parkinson's disease retatrutide clinical trial ly3437943 Incretin triple agonist (LY3437943) alleviates obesity-associated cancer progression Retatrutide Results: 28.3% Weight Loss – Help cure Parkinson's disease: please

This regulatory gap means that patients may be taking supplements of uncertain composition alongside a potent investigational drug

Clinical trials are typically short, tightly controlled, and often exclude patients with histories of depression, anxiety, or suicidal ideation

Really proud of the devices my teams at Lilly and Sanofi created and developed for 3 of these top products (Mounjaro, Dupixent, Zepbound)

Key takeaways include: Obesity drug coverage in Medicaid remains limited, with 13 state Medicaid programs covering GLP-1s for obesity treatment under fee-for-service (FFS) as of January 2026

Why are people choosing GLP-1 microdosing instead of full doses

phentermine 7/ Wegovy vs